Pancreatic Cancer Research

ResearcherDuke UniversityNo recent work listed

Hongyu Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1747-5267; OpenAlex author ID A5100402311. Sources: OpenAlex.

Their work

Papers
22 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: 6 papers · 2015: 5 papers · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 3 papers

Papers 22

  1. Metabolomic Detection Between Pancreatic Cancer and Liver Metastasis Nude Mouse Models Constructed by Using the PANC1-KAI1/CD82 Cell Line. Co-author DOI 10.1177/15330338211045204↗
  2. Evaluation of serum ATX and LPA as potential diagnostic biomarkers in patients with pancreatic cancer. First author DOI 10.1186/s12876-021-01635-6↗
  3. Effects of KAI gene expression on ferroptosis in pancreatic cancer cells. Co-author DOI 10.3892/mmr.2020.11802↗
  4. KAI1 reverses the epithelial-mesenchymal transition in human pancreatic cancer cells. Co-author DOI 10.1016/j.hbpd.2019.03.004↗
  5. Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Co-author DOI 10.1002/ijc.31171↗
  6. Portal Hypertension in a Patient With Recurrent Pancreatic Cancer After Radiotherapy and Systemic Chemotherapy. Co-author DOI 10.1016/j.jceh.2017.11.005↗
  7. Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer in vitro. Co-author DOI 10.3748/wjg.v23.i5.817↗
  8. Src/STAT3 signaling pathways are involved in KAI1-induced downregulation of VEGF-C expression in pancreatic cancer. Co-author DOI 10.3892/mmr.2016.5093↗
  9. Pancreatic cancer: diagnosis and treatments. Co-author DOI 10.1007/s13277-015-3223-7↗
  10. miR-33a suppresses the nuclear translocation of β-catenin to enhance gemcitabine sensitivity in human pancreatic cancer cells. Last author DOI 10.1007/s13277-015-3679-5↗
  11. Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with t… Co-author DOI 10.1177/1535370215571884↗
  12. MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine. Co-author DOI 10.18632/oncotarget.3885↗
  13. Endocrine gland‑derived vascular endothelial growth factor modulates proliferation, apoptosis and migration in pancreatic cancer cells. Co-author DOI 10.3892/mmr.2015.3340↗
  14. Serum carbohydrate antigen 242 expression exerts crucial function in the diagnosis of pancreatic cancer. Co-author DOI 10.1007/s13277-014-1687-5↗
  15. Prognostic significance of cyclooxygenase-2 protein in pancreatic cancer: a meta-analysis. Co-author DOI 10.1007/s13277-014-2260-y↗
  16. KAI1 inhibits lymphangiogenesis and lymphatic metastasis of pancreatic cancer in vivo. Co-author DOI 10.1016/s1499-3872(14)60012-6↗
  17. Diagnostic significance of serum osteopontin level for pancreatic cancer: a meta-analysis. First author DOI 10.1089/gtmb.2014.0102↗
  18. Effect of PTEN and KAI1 gene overexpression on the proliferation, metastasis and radiosensitivity of ASPC‑1 pancreatic cancer cells under hypoxic conditions. Co-author DOI 10.3892/mmr.2014.2404↗
  19. Pim-3 promotes human pancreatic cancer growth by regulating tumor vasculogenesis. Co-author DOI 10.3892/or.2014.3158↗
  20. Pim-3 promotes the growth of human pancreatic cancer in the orthotopic nude mouse model through vascular endothelium growth factor. First author DOI 10.1016/j.jss.2013.06.004↗
  21. Generation of CTL responses against pancreatic cancer in vitro using dendritic cells co-transfected with MUC4 and survivin RNA. Co-author DOI 10.1016/j.vaccine.2013.07.055↗
  22. Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro. First author DOI 10.1111/j.1440-1746.2011.06778.x↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaozhong Guo · 15 shared papers, 2011–2021 · strength 1.10
  2. Jiang Chen · 4 shared papers, 2014–2021 · strength 0.38
  3. Xingshun Qi · 3 shared papers, 2016–2021 · strength 0.33
  4. Xu Liu · 3 shared papers, 2014–2021 · strength 0.30
  5. Wenda Xu · 2 shared papers, 2017–2021 · strength 0.28
  6. Xiaodong Shao · 4 shared papers, 2014–2018 · strength 0.28
  7. Chen Jiang · 2 shared papers, 2013–2021 · strength 0.23
  8. Chen Jiang · 2 shared papers, 2015–2021 · strength 0.22
  9. Jiajun Zhao · 4 shared papers, 2011–2017 · strength 0.21
  10. Xiaozhong Guo · 1 shared paper, 2021 · strength 0.19
  11. Hao Han · 1 shared paper, 2021 · strength 0.17
  12. Shuo Wang · 1 shared paper, 2021 · strength 0.16
  13. Xiaozhong Guo · 1 shared paper, 2021 · strength 0.16
  14. Xu Liu · 1 shared paper, 2021 · strength 0.16
  15. Chen Jiang · 1 shared paper, 2019 · strength 0.14
  16. Xu Liu · 1 shared paper, 2019 · strength 0.14
  17. Linan Ren · 2 shared papers, 2014–2015 · strength 0.12
  18. Yingyi Li · 2 shared papers, 2014–2015 · strength 0.12
  19. Chen Liang · 2 shared papers, 2015 · strength 0.11
  20. Ying-Yi Li · 2 shared papers, 2013–2015 · strength 0.10
  21. Chunyan Wu · 2 shared papers, 2014 · strength 0.10
  22. Zhen Wang · 2 shared papers, 2014–2015 · strength 0.10
  23. Bin Liu · 2 shared papers, 2013–2014 · strength 0.09
  24. James L. Abbruzzese · 1 shared paper, 2018 · strength 0.07
  25. Bensong Duan · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.